Home Blog Page 1343

High Response in Bladder Cancer: Immvira Announced Its MVR-T3011 Latest Clinical Results in BCG-Unresponsive Bladder Cancer Patients at 2025 Annual Meeting of the Society of Urologic Oncology

SUZHOU, China, Dec. 4, 2025 /PRNewswire/ — On December 3, 2025 (local time in Arizona, USA), ImmVira Group (“ImmVira” or the “Company”) announced a poster presentation at the 26th Annual Meeting of the Society of Urologic Oncology (SUO 2025). The presentation featured the latest interim clinical data (as of September 19, 2025) for its lead HSV-1 oncolytic virus product. MVR-T3011, in high-risk BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) patients.

The patients were enrolled and treated with intravesical MVR-T3011 at two dose levels: 2×109 PFU and 1×1010 PFU in this study. There were a total of 26 patients with papillary (16 patients at the dosage level of 2×109 PFU, 10 patients at the dosage level of 1×1010 PFU), and a total of 12 patients with carcinoma in situ (CIS) (7 patients at the dosage level of 2×109 PFU, 5 patients at the dosage level of 1×1010 PFU) enrolled in this trial. Data from the patients demonstrated a promising efficacy profile:

  • Among 16 evaluable patients with BCG-unresponsive papillary who received MVR-T3011 at a dose of 2×109 PFU, the 3-month, 6-month, 9-month and 12-month recurrence-free survival (RFS) rates were 87.1%, 80.4%, 80.4% and 71.4%, respectively. Among 6 evaluable patients who received MVR-T3011 at a dose of 1×1010 PFU, 100% of patients remained recurrence free at Month 3 and Month 6.

Source: The Company’s poster on 2025 SUO.
Source: The Company’s poster on 2025 SUO.

  • As of the same date, among 7 evaluable patients with BCG-unresponsive CIS (with or without Ta/T1) who received MVR-T3011 at doses of 2×109 PFU, the CR at any time, 3-month and 6-month CRR was 71.4%, and among 5 evaluable patients with BCG-unresponsive CIS (with or without Ta/T1) who received MVR-T3011 at doses of 1×1010 PFU, the CR at any time, 3-month and 6-month CRR was 100%.

Source: The Company’s poster on 2025 SUO.
Source: The Company’s poster on 2025 SUO.

Consistent with previous clinical findings, MVR-T3011 continued to demonstrate a favorable safety and tolerability profile in the latest study. Most treatment-emergent adverse events (TEAEs) were at Grades 1 or 2. Only five Grade 3 TEAEs were reported, two of which were treatment-related adverse events (TRAEs) and were consistent with reactions commonly associated with catheterization procedures. No Grade 3 or above TEAEs and no dose-limiting toxicities (DLT) occurred.

According to Frost & Sullivan, bladder cancer is one of the top 10 most common solid tumors globally by incidence and often requires prolonged treatment and surveillance spanning 5-10 years. NMIBC is a main type of bladder cancer, representing approximately 75% of all newly diagnosed bladder cancer cases. The current standard of care for high-risk NMIBC is Bacillus Calmette-Guerin (BCG). However, the availability of BCG is significantly limited by global supply shortages. In the U.S., BCG supply meets less than 30% of the total demand. These significant unmet medical needs highlight a clear opportunity for novel immunotherapies such as oncolytic viruses, which hold considerable potential as a new mechanism of action in this underserved market.

“We are highly encouraged by the interim efficacy data from the study, especially the high CR and RFS rate for both BCG-unresponsive CIS and papillary patients at 1×1010 PFU,” said Dr. Grace Zhou, Chairwoman and CEO of ImmVira. “We have initiated a phase II trial for BCG-unresponsive high-risk NMIBC in the U.S. in June 2025 and are progressing a global multi-regional clinical trial (MRCT) inclusive of China. We believe MVR-T3011 could emerge as the new generation of therapy for patients with high-risk, BCG-unresponsive NMIBC.”

About MVR-T3011

MVR-T3011, represents a breakthrough in HSV-1-based oncolytic immunotherapy. Its proprietary “3-in-1” design unites a replication-competent, tumor-lytic HSV-1 backbone with anti-PD-(L)1 antibody and IL-12, enabling it simultaneously to lyse tumor cells and stimulate innate and adaptive immunity. MVR-T3011 has demonstrated its adaptability and feasibility across multiple routes of administration including intratumoral, intracavitary and intravenous administrations. MVR-T3011 is the world’s first HSV-1-based oncolytic immunotherapy that has completed a phase I trial via systemic intravenous dosing under the FDA regulatory regime.

About ImmVira

ImmVira is a global leading clinical-stage biotechnology company that is powered by proprietary biological engineering technology, and is dedicated to the discovery, development, manufacture and commercialization of novel oncolytic immunotherapies and engineered exosome therapies. We have strategically designed and built a risk-balanced product portfolio that comprised both potentially best-in-class oncolytic immunotherapy candidates for solid tumors and innovative engineered exosome assets for clinical application or direct commercialization. Driven by our strategic priority to become a global leader in the full spectrum of bladder cancer treatment development, we have adopted a rationalized, adaptive approach to advance oncolytic immunotherapy candidates with high clinical potential globally. In parallel, leveraging our deep expertise in biological engineering, we have pioneered development of engineered exosome candidates targeting chronic, hard-to-treat diseases as well as age-related conditions. These selected engineered exosome assets are being deliberately accelerated through strategic, differentiated regulatory pathways to enable expedited commercialization and generate sustainable cash flows that will fuel our broader drug development efforts.

Motorola unveils The Brilliant Collection – reimagining tech as a style statement in partnership with Swarovski®

SYDNEY, Dec. 4, 2025 /PRNewswire/ — Mobile communications leader Motorola has partnered with Swarovski® to launch its Motorola Collections series, The Brilliant Collection.

The Brilliant Collection, featuring the motorola razr 60 and moto buds loop with Sound by Bose
The Brilliant Collection, featuring the motorola razr 60 and moto buds loop with Sound by Bose

This thoughtfully curated set of select devices brings the new moto buds loop with Sound by Bose to Australia for the first time, accompanied by an elevated design of the renowned motorola razr 60 – both products encrusted with crystals by Swarovski®.

The Brilliant Collection signifies how fashion and function can shine in perfect harmony, highlighting how fashion forward design and intelligent technology converge to not only meet the personal tech needs of Australians, but mirror their lives, styles, and values. 

On the partnership, Praveena Raman, Head of Motorola Australia and New Zealand says, “Motorola and Swarovski share a passion deeply rooted in innovation, craftsmanship and iconic heritage, making Swarovski a natural partner for the Motorola Collections series.”

“This collection brings lifestyle luxury to everyday technology. We have embodied Australians’ desire for tech that elevates life, bridging beauty and functionality”

Crystal clear sound meets crystal clear style: moto buds loop with Sound by Bose 

For the first time, the moto buds loop will be available in Australia – Motorola’s first open-ear earbuds – available in an exquisite PANTONE™ Ice Melt colourway. Users can enjoy crystal-clear audio with Sound by Bose that sparkles as brilliantly as the Swarovski crystals, blending exceptional sound quality with distinctive personal style.

The open-ear form allows users to stay connected to their environment while still experiencing great sound, perfect for commuting, running, or simply going about their day. Additionally, the sleek, lightweight frame and refined silhouette are crafted to sit securely and comfortably on the outer ear for a fit that feels as good as it looks, ideal for extended wear without fatigue.

The meticulous attention invested in the stylish design has been matched by the innovative specs, with the earbuds delivering impressive audio thanks to the Sound by Bose technology, 12mm ironless drivers, and spatial sound technology, all delivering a rich, immersive listening experience. With a dual-microphone system and CrystalTalk AI, calls are clear with precise voice capture and minimized background noise. 

The moto buds loop are compatible with any Bluetooth device, and when paired with select Motorola devices, users can access helpful voice-activated actions thanks to moto ai1. Smart Connect also offers easy, uninterrupted switching between Motorola and Lenovo devices. 

Built for busy, on-the-go lifestyles, the moto buds loop feature durable materials, a water-repellent design2, and long-lasting battery life – up to eight hours on a single charge and 37 hours with the case3

The iconic flip phone now cuts a shine above the rest: motorola razr 60 

The motorola razr 60, accented with dazzling Swarovski crystals, stands as the epitome of meticulous craftsmanship and timeless luxury. Featuring a shimmering leather-inspired finish in a 3D quilted pattern in mesmerising PANTONE Ice Melt, this device showcases 35 precisely hand-positioned Swarovski crystals, including one larger gem with 26 facets positioned on the hinge, delivering vibrant and sparkling brilliance. Even the volume keys feature a crystal-inspired design that adds an extra touch of elegance. 

Users can enjoy all the features that the motorola razr 60 has been praised for, from its 50MP camera system with moto ai integration delivering stunning photos in any light, to its 3.6″ external display, offering access to favourite apps, without having to flip open the phone.

The iconic razr design has always turned heads – now every crystal elevates its instantly recognisable silhouette, transforming it into a couture creation that radiates confidence and commands attention from every angle. 

The next chapter of lifestyle luxury and smart tech 

Motorola Collections are thoughtfully curated sets of select devices connected through inspired themes, cohesive design languages, or impactful brand collaborations. With every collection, Motorola will spotlight elite craftsmanship, purposeful innovation, and unexpected pairings that redefine how personal technology looks and feels. 

This dazzling collaboration is just the beginning for Motorola Collections, with limited quantities available and more curated device collections to follow. 

Availability 

The Brilliant Collection will be available in PANTONE Ice Melt, exclusively at Harvey Norman from 4 December 2025. The motorola razr 60 is available for RRP $1,499, and the moto buds loop with Sound by Bose is available for RRP $399.

For a limited time, purchase the motorola razr 60 and moto buds loop in the same transaction and receive a $300 discount. Offer ends 24 December 2025. Terms and conditions apply.

Follow Motorola Australia on Facebook, Instagram and TikTok.  

– ENDS – 

For full pricing information and specifications, visit motorola.com.au for further information or review devices, please contact the Motorola PR team at Zeno Group  

Legal disclaimers: 

MOTOROLA, the Stylised M Logo, MOTO and the MOTO family of marks are trademarks of Motorola Trademark Holdings, LLC. Bose and sound by Bose are trademarks of Bose Corporation. The Pantone colour reference and the PANTONE Chip Design are used with the permission of Pantone LLC. © Pantone LLC, 2025. All rights reserved. This is an authorized Pantone-licensed product manufactured by Motorola. Google and Android are trademarks of Google LLC. Swarovski® is a registered trademark of Swarovski AG. All other trademarks are the property of their respective owners. © 2025 Motorola Mobility LLC.

  1. moto ai features are only available on select Motorola devices.
  2. Water-repellent design creates a barrier to help protect against moderate exposure to fresh water such as accidental spills, splashes or light rain. Not designed to be submerged in water, or exposed to pressurized water, or other liquids; may diminish over time. Not waterproof.
  3. Battery must be substantially depleted; charging rate slows as charging progresses.  All battery life claims are approximate and based on optimal conditions. Actual battery performance will vary and depends on many factors including device settings, temperature, battery condition, and usage patterns.

 

The Brilliant Collection, featuring the motorola razr 60 and moto buds loop with Sound by Bose
The Brilliant Collection, featuring the motorola razr 60 and moto buds loop with Sound by Bose

The Brilliant Collection, featuring the motorola razr 60 and moto buds loop with Sound by Bose
The Brilliant Collection, featuring the motorola razr 60 and moto buds loop with Sound by Bose

IKEA opens first store in New Zealand, brings home furnishings virtually across country

MALMÖ, Sweden, Dec. 4, 2025 /PRNewswire/ — Two years and three months after the groundbreaking ceremony in Sylvia Park, Auckland, IKEA has officially said ‘Kia ora’ and opened its first store in New Zealand. At the same time, the IKEA range is available throughout the country via IKEA.com and the IKEA app, with nationwide delivery and planning services.

IKEA New Zealand opening
IKEA New Zealand opening

The long-anticipated store and its 500 co-workers welcomed crowds of excited Kiwis. Once through the doors, customers experienced styled room-sets and more than 7,500 products, convenient services, and plenty of inspiration.

“We’re thrilled to bring IKEA all the way to New Zealand, the country that’s geographically the furthest from our Swedish beginnings. That distance makes this opening special,” said Tolga Öncü, Ingka Retail Manager (COO), Ingka Group | IKEA. “Coming to New Zealand is a real leap of faith, investment and friendship, showing we’re not just exporting a store. We’re planting roots for the long term.”

For the first time when opening a new market, IKEA has set up 29 pick-up points around the country, where customers can collect their purchases even more affordably. The new IKEA store in Auckland, pick-up points and online and remote sales complement each other in an omnichannel way, allowing the Swedish retailer to get closer to the shopping preferences of New Zealanders. In addition, a Buy Back service is available at the store from day one – even for non-IKEA products – supporting circular living and reducing waste.

Ahead of the store opening, IKEA has visited more than 500 homes in New Zealand to understand the life at home expectations of the many Kiwis and translate those learnings into its store and online presentation. It also collected those insights into its first Life at Home Report about New Zealand, and organized housewarming celebrations in locations across Auckland, reflecting the Kiwi lifestyle – from backyard gatherings to late-night garage jams and sunny mornings by the sea.

New Zealand is the first new market for the largest IKEA retailer since 2021, when a store opened in Ljubljana, capital of Slovenia.

The expansion into New Zealand is part of a broader investment strategy aimed at making IKEA even more accessible worldwide. In total, more than EUR 5 billion will be invested by FY27 in opening new locations and optimizing the existing ones across many markets.

 

AVENUE DES CHAMPS-ELYSÉES CELEBRATES THE REVIVAL OF ITS SIGNATURE COCKTAIL: THE “CHAMPS-ÉLYSÉES COCKTAIL” FIRST CREATED IN 1925 WITH COGNAC HENNESSY

1925–2025: A Century of Parisian Art de Vivre

PARIS, Dec. 4, 2025 /PRNewswire/ — Born in the Roaring Twenties, the “Champs-Élysées Cocktail” has, since 1925, embodied the elegance, flair, and joie de vivre that have long defined the world’s most celebrated avenue. To mark its 100th anniversary, the avenue’s landmark establishments united by the Champs-Élysées Committee, honor this iconic signature drink and inviting guests to rediscover a cocktail that has accompanied Parisian nights for decades.

Cocktail Champs-Elysées 1925 by Hennessy, the original recipe
Cocktail Champs-Elysées 1925 by Hennessy, the original recipe

The original recipe, the “Cocktail Champs-Élysées 1925,” along with two exclusive new creations – the boldly reimagined “Cocktail Champs-Élysées 2.0” and the alcohol-free “Mocktail Champs-Elysées” – will be featured across participating venues and can be recreated at home.

COCKTAIL CHAMPS-ELYSÉES 1925 By Hennessy, the original recipe

4,5cl Hennessy Very Special |1,5cl Yellow Chartreuse | 2cl Fresh lemon juice | 1 dash Angostura bitters | 1 Lemon twist

COCKTAIL CHAMPS-ELYSÉES 2.0 By Hennessy, the contemporary version

4cl Hennessy Very Special | 1cl Yellow Chartreuse | 1,5cl Apricot liqueur | 2cl Verjus | 1 dash Peychauds bitters

Cocktail Champs-Elysées 2.0 by Hennessy, the contemporary version
Cocktail Champs-Elysées 2.0 by Hennessy, the contemporary version

ABOUT MAISON HENNESSY

Maison Hennessy has shone around the world with its exceptional know-how for more than 260 years. Built on founder Richard Hennessy’s legacy, the brand is present in more than 160 countries. Based in the heart of the Charente French region, Hennessy is also a pillar of the regional economy. The House’s success and longevity are rooted in the excellence of its cognacs, each of which is born of a unique process of transmission of know-how from generation to generation. The first spirits house to be certified ISO 14001, Hennessy unites its capacity for innovation and the support of all of its partners to protect this exceptional area. As a crown jewel of the LVMH Group, Hennessy is a major contributor to French international trade, with a large part of its production sold in export, and a worldwide ambassador for the French art de vivre.

PRESS CONTACT Maison Hennessy – Fatima El Allay – felallaly@hennessy.fr 

www.hennessy.com 

ABOUT THE CHAMPS-ÉLYSÉES COMMITTEE

The Champs-Élysées Committee was founded in 1916 and represents 180 members – the economic and cultural stakeholders of the Champs-Élysées, from the Arc de Triomphe to Place de la Concorde. Together, they contribute to the avenue’s prominence in France and internationally. Each year, the Champs-Élysées Committee organizes the famous Christmas Light Displays and big-scale events such as “A Sunday at the Movies on the Champs,” “The Champs Dictation,” and “The Champs Grand Picnic“. In 2025, the Committee revived the Champs-Élysées cocktail in partnership with Hennessy.

PRESS CONTACT Agence Proches – comitechampselysees@agenceproches.com 

PLEASE DRINK RESPONSIBLY

 

Mitrade CFD Broker Caps 2025 With New Licence, Expanded Market Access and Record 16 Awards Amid a 20% Expansion in Its User Base

MELBOURNE, Australia, Dec. 4, 2025 /PRNewswire/ — Mitrade remains positioned as a globally recognised global CFD trading platform and broker regulated by ASIC, CySEC, CIMA, FSC and FSCA, serving traders across more than 119 countries with a user community that previously exceeded 5 million. The platform continues to enhance its offerings through accessibility, transparency and responsible trading, supported by multi-licence supervision and comprehensive trading education.

The 2025 reporting cycle shows clear expansion across several operational and market areas, including:

  • A new FSCA licence, strengthening Mitrade’s regulatory presence in Africa.
  • A broadened product offering, increasing from 500 to 800 CFD instruments.
  • Three additional customer support languages—German, Italian and Arabic—raising CX coverage to 12 languages.
  • Four new platform languages—Thai, Italian, Arabic and German—expanding to 16 languages.
  • A 20% increase in the global user base, growing from 5 million to 6 million.
  • Two million new app downloads, bringing total downloads to 14.6 million.
  • Sixteen international awards in 2025, lifting the cumulative total to 56 awards, the platform’s highest annual recognition to date.

“These milestones highlight meaningful progress across oversight, accessibility and user engagement,” Elven Jong, CEO of Mitrade AU, said. “A broader product range, support capabilities and stronger regulatory alignment continue to guide how Mitrade’s growing community participates responsibly.”

Mitrade maintains its positioning as a multi-asset CFD trading platform offering one-stop access to forex, indices, commodities, shares and ETFs. The broker’s intuitive platform anchored in proprietary technology enables fast execution and seamless navigation across devices. Improved instrument coverage and multilingual support contribute to an inclusive environment shaped by Mitrade’s mission to foster equitable participation in the global CFD sector.

About Mitrade

Mitrade is an award-winning CFD trading platform founded in Melbourne, trusted by 6M+ traders worldwide. It operates under top-tier financial regulators—Australia’s ASIC (AFSL398528), Cyprus’ CySEC (CIF438/23), the Cayman Islands’ CIMA (SIB1612446), South Africa’s FSCA (54842), and Mauritius’s FSC (GB20025791)—delivering a secure, seamless, and intuitive trading experience.

The platform provides 800+ CFDs on indices, forex, commodities, ETFs, and shares. Mitrade redefines trading with microsecond execution, razor-thin spreads, robust risk management, and multi-device compatibility.

Trading involves risk. This article is for informational purposes only and does not constitute financial advice, an offer, or a solicitation.

Visit https://www.mitrade.com for more information.

6K ADDITIVE SECURES A$48 MILLION THROUGH INITIAL PUBLIC OFFERING ON THE AUSTRALIAN STOCK EXCHANGE

New capital will drive major increases in metal-powder production capacity and new ingot melt capabilities

Highlights:

  • 6K Additive, Inc. (6K Additive or the Company) commences trading on the ASX under ticker symbol ‘6KA’.
  • Well-supported Initial Public Offering (IPO) which raised A$48m at an Offer Price of A$1.00 per CHESS Depositary Interest (CDIs), resulting in a market capitalisation based on the Offer Price of A$267m and an enterprise value of A$206m.
  • The current Burgettstown expansion plan, as detailed under the Company’s DPA Title III Grant, is fully funded following the IPO raise, with the potential to facilitate a 5x increase in powder production, site consolidation, and the addition of ingot melt capability.
  • The Company’s US$27.4m loan from the EXIM Loan in partnership with the United States Department of War approval announced last week provides flexibility for additional growth initiatives beyond the current expansion plan.
  • The Company continues to experience strong demand for its premium metal powders and is supporting this growth through higher production volumes and improved operational performance.
  • 6KA will host an Investor Webinar tomorrow Friday, 5 December 2025 at 11.30am Sydney time to provide an overview of the Company and discuss recent achievements.

BURGETTSTOWN, Pa., Dec. 4, 2025 /PRNewswire/ — 6K Additive, a global leader in advanced metal powders and alloy additions, today announced the successful completion of its IPO on the Australian Stock Exchange (ASX), raising A$48m at an offer price of A$1.00 per CDI (Offer Price). At the Offer Price, 6K Additive has an initial market capitalization of approximately A$267m and an enterprise value of approximately A$206m. The Company’s CDIs will trade on ASX under the ticker symbol 6KA. The IPO attracted strong support from a range of new institutional, family office and sophisticated investors in Australia and overseas, together with existing shareholders. Trusted by leading organizations across aerospace, defense, space, medical, energy, and automotive sectors, 6K Additive plans to use the newly secured capital to support its expansion plan to better serve its growing customer base and broaden its product offerings.

Expansion plan

The combination of IPO proceeds and a US$23.4m grant from the US Department of War’s Defense Production Act Title III enables 6K Additive to scale its metal-powder production capacity to over five times its current output, from ~200 metric tons to 1,000 metric tons, and initiate commercial ingot production capability. Construction is already underway at the Company’s 45-acre global headquarters in Burgettstown, PA. Plans include expanding the existing powder-production operations with space for up to ten additional UniMelt® systems, adding new structures for feedstock preparation, melting operations for ingots, and building a dedicated refractory production facility.

Newly Secured EXIM Loan

The IPO comes on the heels of 6K Additive’s recent media release of the approval of a US$27.4m Export-Import Bank low-cost long-term loan facility (EXIM Loan). The EXIM Loan builds upon the DPA Title III Grant of US$23.4m to finance the construction of four new buildings and the acquisition of advanced equipment to produce titanium, nickel powders and alloy additions.

With the combination of IPO proceeds, the DPA Title III Grant, and the new EXIM Loan, 6K Additive is well-capitalised to:

  • Complete its near-term capacity expansion program at its global headquarters campus in Burgettstown, PA on schedule;
  • Invest in additional UniMelt® plasma systems and downstream processing equipment to significantly scale titanium and high-performance nickel alloy powder production; and
  • Pursue strategic growth opportunities with key clients in the aerospace, defence, energy, and industrial sectors.

Sales Pipeline Grows to US$240m

6K Additive’s sales pipeline has expanded to US$240m as at end of November 2025, marking a US$10m increase over the past two months. This growth highlights the strong demand for 6K Additive’s premium metal powders. As demand is expected to continue to grow, 6K Additive remains committed to scaling production and optimizing operating metrics to deliver exceptional value to its customers and partners.

“The IPO and resulting capital fast-track the realization of our vision and achieve the scale with attractive unit economics and unique material breadth required by customers in defense, aerospace, energy, and medical markets,” said Frank Roberts, CEO and Managing Director of 6K Additive. “As a strategic supplier to the U.S. Department of War and its Tier-1 contractors, our products, production processes and technology have been qualified in their supply chains, reinforcing these relationships. This growth enables a domestic supply of critical materials for applications such as hypersonics, nuclear fusion, medical implants, and rocket-engine development.”

David Seldin, 6K Additive Chairman of the Board and Managing Partner of Anzu Partners commented, “As an institutional investor in 6K Additive from its inception, I witnessed this organisation grow to the leading domestic provider of metal powders and alloy additions. The breadth and quality of 6K Additive’s products, the trusted relationship with the US Department of War and the dedicated employee talent, underscores the potential this organization has in the coming 3-5 years.” 

Investor webinar

6K Additive will host an investor webinar tomorrow, Friday 5 December 2025 at 11.30am Sydney time to provide an overview of the Company, its strategy and recent achievements, and to answer investor questions. Click below to register.

https://6kadditive.zoom.us/webinar/register/WN_sIwNJqjdRCqLjkHop6l1BA

Organizations seeking to collaborate with 6K Additive on specialized powder requirements are encouraged to visit www.6KAdditive.com and contact the Company directly.

About 6K Additive

6K Additive, Inc. (ASX:6KA) is a US-based manufacturer and trusted supplier of premium metal powders for additive manufacturing and alloy additions for the aluminum melt industry, all made from sustainable sources. Headquartered in Burgettstown, PA, the Company’s manufacturing process produces the highest quality metal powders that are truly spherical, void of porosity and satellites with better unit economics than competing technologies. 6K Additive utilizes proprietary UniMelt® microwave plasma system to produce the industry’s most comprehensive portfolio of metal powder including a variety of Nickel, Titanium, Copper, and refractory powders that include, Tungsten, Rhenium, Niobium/C-103 and Tantalum. 6K Additive leverages feedstock such as certified turnings, millings, used additive powder, support material and failed builds that provide customers sustainable, domestically sourced metal powder. 

This announcement has been approved for release by Frank Roberts, Managing Director and Chief Executive Officer. 

Forward Looking Statements

This announcement contains forward-looking statements. Forward-looking statements may include statements regarding 6K Additive’s intentions, objectives, plans, expectations, assumptions and beliefs about future events, including 6K Additive’s expectations with respect to the financial and operating position or performance of its business, its capital position and future growth. Forward-looking statements are based on assumptions and contingencies that are subject to change without notice and are not guarantees of future performance. They involve known and unknown risks, uncertainties and other important factors, many of which are beyond the control of 6K Additive, its directors and management and which may cause actual outcomes to differ materially from those expressed or implied in this announcement, including but not limited to, the factors described in the “Risk Factors” section of the Company’s Replacement Prospectus dated 11 November 2025. Readers are cautioned not to place undue reliance on forward-looking statements, which are provided for illustrative purposes only and are not necessarily a guide to future performance. No representation or warranty is made by any person as to the likelihood of achievement or reasonableness of any forward-looking statements, and to the maximum extent permitted by law, responsibility for the accuracy or completeness of any forward-looking statements is disclaimed, and except as required by law or regulation (including ASX Listing Rules), 6K Additive undertakes no obligation to update any forward-looking statements. 6K Additive also notes that past performance may not be a reliable indicator of future performance.

Restriction on purchases of CDIs by US persons

6K Additive is incorporated in the US State of Delaware and its CDIs have not been registered under the US Securities Act of 1933 or the laws of any state or other jurisdiction in the United States. Trading of the CDIs on the ASX is not subject to the registration requirements of the US Securities Act in reliance on Regulation S under the US Securities Act and a related ‘no action’ letter issued by the US Securities and Exchange Commission to the ASX in 2000. As a result, the CDIs are “restricted securities” (as defined in Rule 144 under the US Securities Act) and may not be sold or otherwise transferred except in transactions exempt from, or not subject to, the registration requirements of the US Securities Act. For instance, US persons may purchase CDIs if they are “qualified institutional buyers” (“QIBs”, as defined in and in reliance on the exemption from registration provided by Rule 144A under the US Securities Act).  To enforce the transfer restrictions, the CDIs bear a FOR Financial Product designation on the ASX. This designation restricts any CDIs from being sold on ASX to US persons excluding QIBs. In addition, hedging transactions with regard to the CDIs may only be conducted in compliance with the US Securities Act.

POMDOCTOR LIMITED Announces First Half of Fiscal 2025 Unaudited Financial Results

GUANGZHOU, China, Dec. 4, 2025 /PRNewswire/ — Pomdoctor Limited (“Pomdoctor” or the “Company”) (NASDAQ: POM), a leading online medical services platform for chronic diseases in China, today announced its unaudited financial results for the six months ended June 30, 2025.

Mr. Zhenyang Shi, Chairman and Chief Executive Officer of Pomdoctor, commented: “The first half of fiscal year 2025 reflected our deliberate and disciplined efforts to balance business expansion with operational rigor. Despite a challenging macroeconomic environment and intensified market competition, we strived to strengthen our market coverage and penetration, while optimizing and diversifying our revenue streams through the vigorous promotion of our internet-hospital services and online sales. During the period, we continued to solidify our partner-doctor pool by offering higher service fees, and at the same time meaningfully enhanced our collaboration with pharmaceutical manufacturers to drive online sales and adapt to China’s evolving healthcare landscape. These initiatives resulted in a 16.2% increase in net revenue, highlighted by growth of 83.2% in our online-pharmacy businesses.

At the same time, we maintained strict cost controls and operational discipline, sustaining a stable gross profit margin of 16.2%. Gross profit increased 16.3% year over year, despite higher sales and marketing expenses, a larger contribution from lower-margin pharmacy products, and continued investments in customer acquisition. We prioritized retaining doctor resources while prudently reducing advertising spending, reinforcing the foundation for sustainable growth under a stable pharmaceutical supply chain.

Notably, our successful initial public offering (IPO) in October provided us with additional capital resources and expanded opportunities for future growth, further enriching our strategic options and strengthening our execution capabilities. Looking ahead, we are confident in our ability to continue improving operational performance and creating long-term value for our shareholders.”

First Half of Fiscal 2025 Financial Summary

  • Net revenues for the six months ended June 30, 2025 were RMB174.5 million (US$24.4 million), representing a 16.2% increase from RMB150.2 million in the six months ended June 30, 2024.
  • Gross profit increased by 16.3% from RMB24.3 million in the six months ended June 30, 2024, to RMB28.3 million (US$4.0 million) in the six months ended June 30, 2025.
  • Gross profit margin remained stable at 16.2% in the six months ended June 30, 2024 and 2025.
  • Net loss was RMB19.9 million (US$2.8 million) for the six months ended June 30, 2025, compared with RMB14.0 million for the six months ended June 30, 2024.
  • Net loss per share, basic and diluted, was RMB11.45 (US$1.60) for the six months ended June 30, 2025, compared with RMB10.58 for the six months ended June 30, 2024.

Unaudited Financial Results for the First Half of Fiscal 2025

  • Net revenues for the six months ended June 30, 2025 were RMB174.5 million (US$24.4 million), representing a 16.2% increase from RMB150.2 million in the six months ended June 30, 2024, which was primarily attributable to the increase in the net revenues from Internet hospital. Net revenues from Internet hospital increased by 82.4% from RMB36.8 million in the six months ended June 30, 2024 to RMB67.2 million (US$9.4 million) in the six months ended June 30, 2025, primarily attributable to the increase in revenues generated from online pharmacy sales. In the first half of 2025, the Company strengthened its cooperation with pharmaceutical manufacturers to sell their products through its Internet hospital platform. As a result, revenue from the Company’s online pharmacy sales increased from RMB36.3 million in the six months ended June 30, 2024 to RMB66.4 million (US$9.3 million) in the six months ended June 30, 2025.
  • Cost of revenues increased by 16.2% from RMB125.8 million in the six months ended June 30, 2024 to RMB146.2 million (US$20.4 million) in the six months ended June 30, 2025, primarily due to the increase in cost of revenues in online pharmacy sales from RMB20.4 million in the six months ended June 30, 2024 to RMB40.0 million (US$5.6 million) in the six months ended June 30, 2025, which was in line with the increase in the Company’s net revenues from Internet hospital.
  • Gross profit increased by 16.3% from RMB24.3 million for the six months ended June 30, 2024, to RMB28.3 million (US$4.0 million) in the six months ended June 30, 2025.
  • Gross profit margin remained stable at 16.2% in the six months ended June 30, 2024 and 2025. The gross profit margin of the Company’s Internet hospital decreased from 44.7% in the six months ended June 30, 2024 to 40.5% in the six months ended June 30, 2025, mainly due to the increase in the online pharmacy sales of products with lower gross profit margin. The gross profit margin of the Company’s pharmaceutical supply chain business decreased from 6.9% in the six months ended June 30, 2024 to 1.1% in the six months ended June 30, 2025, which was primarily because the gross profit margin of the Company’s pharmacy wholesale customers newly acquired in the six months ended June 30, 2024 was higher than that of customers in the six months ended June 30, 2025.
  • Sales and marketing expenses increased by 11.6% from RMB24.9 million in the six months ended June 30, 2024 to RMB27.8 million (US$3.9 million) in the six months ended June 30, 2025, primarily due to higher service fees to doctors and increased staff costs in line with the growth in revenues from Internet hospital business, partially offset by a slight decrease in advertising and promotion costs resulting from a relatively stable pharmaceutical supply chain business.
  • General and administrative expenses increased by 53.5% from RMB6.8 million in the six months ended June 30, 2024 to RMB10.5 million (US$1.5 million) in the six months ended June 30, 2025, primarily due to the increase in consultancy and professional service fees incurred in connection with the Company’s initial public offering, partially offset by the decrease in expected credit loss recognized resulting from the efforts for collection of receivables.
  • Research and development expense remained relatively stable at RMB1.5 million (US$0.2 million) for the six months ended June 30, 2024 and 2025.
  • Impairment loss on long-lived assets recorded was RMB0.02 million and RMB2.0 million (US$0.3 million) for the six months ended June 30, 2024 and 2025, respectively.
  • Loss from operation was RMB13.5 million (US$1.9 million) for the six months ended June 30, 2025, compared with RMB8.9 million for the six months ended June 30, 2024.
  • Net loss was RMB19.9 million (US$2.8 million) for the six months ended June 30, 2025, compared with RMB RMB14.0 million for the six months ended June 30, 2024.
  • Net loss per share, basic and diluted, was RMB11.45 (US$1.60) for the six months ended June 30, 2025, compared with RMB10.58 for the six months ended June 30, 2024.

Financial Condition

  • Cash and cash equivalents of RMB5.7 million (US$0.8 million) as of June 30, 2025, compared to RMB7.7 million as of December 31, 2024.
  • Net cash used in operating activities was RMB15.0 million (US$2.1 million) for the six months ended June 30, 2025, compared with RMB10.6 million for the six months ended June 30, 2024.
  • Net cash used in investing activities was RMB512,200 (US$71,500) for the six months ended June 30, 2025, compared with RMB17,862 for the six months ended June 30, 2024.
  • Net cash provided by financing activities was RMB13.6 million (US$1.9 million) for the six months ended June 30, 2025, compared with RMB16.6 million for the six months ended June 30, 2024.

Exchange Rate Information

This announcement contains translations of certain RMB amounts into U.S. dollars at a specified rate solely for the convenience of the reader. Unless otherwise noted, all translations from RMB to U.S. dollars are made at a rate of RMB7.1636 to US$1.00, the rate set forth in the H.10 statistical release of the U.S. Federal Reserve Board on June 30, 2025.

Recent Development

On October 9, 2025, the Company completed its initial public offering (the “Offering”) of 5,000,004 American Depositary Shares (“ADSs”) at a public offering price of US$4.00 per ADS. On October 10, 2025, the underwriter of the Offering fully exercised its over-allotment option to purchase an additional 750,000 American Depositary Shares of the Company at the public offering price of US$4.00 per share. The gross proceeds were US$23,000,016 from the Offering, before deducting underwriting discounts and commissions, and other expenses. The Company’s ADSs began trading on the Nasdaq Global Market on October 8, 2025 under the ticker symbol “POM.”

About POMDOCTOR LIMITED

POMDOCTOR LIMITED is a leading online medical services platform for chronic diseases in China, ranking sixth on China’s Internet hospital market based on the number of contracted doctors in 2022, according to Frost & Sullivan. Focusing on chronic disease management and pharmaceutical services, the Company offers a one-stop platform for medical services, organically connecting patients with doctors and pharmaceutical products. The Company’s operations primarily include Internet hospital and pharmaceutical supply chain, connecting users, pharmacies, suppliers, medical professionals, and other healthcare participants. Through this model, POMDOCTOR aims to enhance the efficiency and transparency of the healthcare value chain. The Company’s mission is to provide effective prevention and treatment solutions to alleviate patients’ sufferings from illnesses. Its vision is to become the most trustworthy medical and healthcare services platform. For more information, please visit the Company’s website: http://ir.7shiliu.com.

Forward-Looking Statements

Certain statements in this announcement are forward-looking statements. These forward-looking statements involve known and unknown risks and uncertainties and are based on the Company’s current expectations and projections about future events that the Company believes may affect its financial condition, results of operations, business strategy and financial needs. Investors can find many (but not all) of these statements by the use of words such as “approximates,” “believes,” “hopes,” “expects,” “anticipates,” “estimates,” “projects,” “intends,” “plans,” “will,” “would,” “should,” “could,” “may” or other similar expressions. The Company undertakes no obligation to update or revise publicly any forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations, except as may be required by law. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results and encourages investors to review other factors that may affect its future results in the Company’s filings with the SEC.

For more information, please contact:

POMDOCTOR LIMITED
Investor Relations Department
Email: ir@7lk.com

Ascent Investor Relations LLC
Tina Xiao
Phone: +1-646-932-7242
Email: investors@ascent-ir.com

 

 

 

POMDOCTOR LIMITED

UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS

December 31,
2024

June 30,
2025

June 30,
2025

RMB

RMB

US$

Assets

Current assets:

Cash and cash equivalents (including amounts of the consolidated VIEs of
   RMB7,596,708 and RMB5,579,802 (US$778,910) as of December 31,
   2024 and June 30, 2025, respectively)

7,651,695

5,746,989

802,249

Accounts receivable, net (including amounts of the consolidated VIEs of
   RMB8,374,608 and RMB6,128,066 (US$855,445) as of December 31,
   2024 and June 30, 2025, respectively)

8,374,608

6,128,066

855,445

Accounts receivable – a related party (including amounts of the
   consolidated VIEs of RMB424,259 and RMB584,802 (US$81,635) as
   of December 31, 2024 and June 30, 2025, respectively)

424,259

584,802

81,635

Amount due from related parties (including amounts of the consolidated
   VIEs of RMB6,070,945 and RMB9,643,039 (US$1,346,117) as of
   December 31, 2024 and June 30, 2025, respectively)

5,632,987

7,418,671

1,035,607

Inventories (including amounts of the consolidated VIEs of
   RMB9,165,973 and RMB6,447,637 (US$900,055) as of December 31,
   2024 and June 30, 2025, respectively)

9,165,973

6,447,637

900,055

Other receivables, net (including amounts of the consolidated VIEs of
   RMB5,318,724 and RMB5,231,722 (US$730,319) as of December 31,
   2024 and June 30, 2025, respectively)

5,318,724

5,231,722

730,319

Advances to suppliers (including amounts of the consolidated VIEs of
   RMB929,167 and RMB2,921,966 (US$407,891) as of December 31,
   2024 and June 30, 2025, respectively)

929,167

2,921,966

407,891

Total current assets

37,497,413

34,479,853

4,813,201

Non-current assets:

Property and equipment, net (including amounts of the consolidated VIEs
   of RMB461,362 and RMB394,107 (US$55,015) as of December 31,
   2024 and June 30, 2025, respectively)

461,362

394,107

55,015

Other non-current assets (including amounts of the consolidated VIEs of
   RMB831,132 and RMB1,307,832 (US$182,566) as of December 31,
   2024 and June 30, 2025, respectively)

831,132

1,307,832

182,566

Deferred offering costs (including amounts of the consolidated VIEs of
   RMB7,437,679 and RMB6,007,339 (US$838,592) as of December 31,
   2024 and June 30, 2025, respectively)

7,437,679

7,690,157

1,073,505

Total non-current assets

8,730,173

9,392,096

1,311,086

Total assets

46,227,586

43,871,949

6,124,287

POMDOCTOR LIMITED

UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS — (Continued)

December 31,
2024

June 30,
2025

June 30,
2025

RMB

RMB

US$

Liabilities

Current liabilities:

Accounts payable (including amounts of the consolidated VIEs of
   RMB25,320,486 and RMB25,164,804 (US$3,512,871) as of December
   31, 2024 and June 30, 2025, respectively)

25,320,486

25,164,804

3,512,871

Accounts payable – a related party (including amounts of the consolidated
   VIEs of RMB25,891 and RMB13,711 (US$1,914) as of December 31,
   2024 and June 30, 2025, respectively)

25,891

13,711

1,914

Short-term bank loans (including amounts of the consolidated VIEs of
   RMB34,958,333 and RMB34,708,333 (US$4,845,096) as of December
   31, 2024 and June 30, 2025, respectively)

34,958,333

34,708,333

4,845,096

Long-term bank loans, current (including amounts of the consolidated
   VIEs of RMB300,000 and RMB2,400,000 (US$335,027) as of
   December 31, 2024 and June 30, 2025, respectively)

300,000

2,400,000

335,027

Long-term loans, current (including amounts of the consolidated VIEs of
   RMB10,000,000 and RMB10,000,000 (US$1,395,946) as of December
   31, 2024 and June 30, 2025, respectively)

10,000,000

10,000,000

1,395,946

Long-term loans from third parties, current (including amounts of the
   consolidated VIEs of RMB2,320,082 and RMB2,295,082
   (US$320,381) as of December 31, 2024 and June 30, 2025,
   respectively)

2,320,082

2,295,082

320,381

Salary and welfare payable (including amounts of the consolidated VIEs   
   of RMB15,375,537 and RMB15,543,259 (US$2,169,755) as of
   December 31, 2024 and June 30, 2025, respectively)

15,375,537

15,543,259

2,169,755

Advance from customers (including amounts of the consolidated VIEs of
   RMB1,756,046 and RMB942,724 (US$131,599) as of December 31,
   2024 and June 30, 2025, respectively)

1,756,046

942,724

131,599

Value added tax (“VAT”) and other tax payable (including amounts of the
   consolidated VIEs of RMB815,462 and RMB998,295 (US$139,357) as
   of December 31, 2024 and June 30, 2025, respectively)

815,462

998,295

139,357

Other payables (including amounts of the consolidated VIEs of
   RMB12,888,550 and RMB10,543,238 (US$1,471,777) as of December
   31, 2024 and June 30, 2025, respectively)

12,888,750

10,543,438

1,471,806

Accrued liabilities (including amounts of the consolidated VIEs of
   RMB9,712,966 and RMB11,564,144 (US$1,614,292) as of December
   31, 2024 and June 30, 2025, respectively)

9,712,966

11,564,144

1,614,292

Short-term loans from third parties (including amounts of the consolidated
   VIEs of RMB11,551,614 and RMB7,194,342 (US$1,004,291) as of
   December 31, 2024 and June 30, 2025, respectively)

11,551,614

7,194,342

1,004,291

Loans from related parties, current (including amounts of the consolidated
   VIEs of RMB13,821,875 and RMB33,194,670 (US$4,633,797) as of
   December 31, 2024 and June 30, 2025, respectively)

13,821,875

33,194,670

4,633,797

Amount due to related parties (including amounts of the consolidated
   VIEs of RMB36,829,010 and RMB42,403,073 (US$5,919,241) as of
   December 31, 2024 and June 30, 2025, respectively)

36,829,010

42,403,073

5,919,241

POMDOCTOR LIMITED

UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS — (Continued)

December 31,
2024

June 30,
2025

June 30,
2025

RMB

RMB

US$

Operating lease liabilities, current (including amounts of the
   consolidated VIEs of RMB1,388,863 and RMB1,790,319
   (US$249,919) as of December 31, 2024 and June 30, 2025,
   respectively)

1,388,863

1,790,319

249,919

Other current liabilities (including amounts of the consolidated
   VIEs of RMB2,080,556 and RMB237,580 (US$33,165) as of  
   December 31, 2024 and June 30, 2025, respectively)

2,080,556

237,580

33,165

Total current liabilities

179,145,471

198,993,774

27,778,457

Long-term bank loans, noncurrent (including amounts of the
   consolidated VIEs of RMB8,400,000 and RMB5,700,000
   (US$795,689) as of December 31, 2024 and June 30, 2025,
   respectively)

8,400,000

5,700,000

795,689

Loans from related parties, noncurrent (including amounts of the
   consolidated VIEs of RMB356,690,859 and RMB356,390,859
   (US$49,750,246) as of December 31, 2024 and June 30, 2025,
   respectively)

356,690,859

356,390,859

49,750,246

Operating lease liabilities, noncurrent (including amounts of the
   consolidated VIEs of RMB1,672,218 and RMB2,346,664
   (US$327,582) as of December 31, 2024 and June 30, 2025,
   respectively)

1,672,218

2,346,664

327,582

Total non-current liabilities

366,763,077

364,437,523

50,873,517

Total liabilities

545,908,548

563,431,297

78,651,974

Commitments and contingencies

Mezzanine equity

Convertible redeemable preferred shares (US$0.0001 par value;
   12,597,228 shares authorized, issued and outstanding as of
   December 31, 2024 and June 30, 2025)

1,595,051,558

1,642,498,390

229,283,934

Redeemable non-controlling interests

168,671,234

173,630,137

24,237,833

Total mezzanine equity

1,763,722,792

1,816,128,527

253,521,767

Equity (deficit)

Class A ordinary shares (US$0.0001 par value; 485,360,730
   shares authorized, 4,268,156 shares issued and outstanding as of
   December 31, 2024 and June 30, 2025)

2,988

2,988

417

Class B Ordinary shares (US$0.0001 par value; 2,042,042 shares
   authorized and outstanding as of December 31, 2024 and
   June 30, 2025, respectively)

1,408

1,408

197

Subscription receivable

(1,608)

(1,608)

(224)

Accumulated deficit

(2,263,419,477)

(2,335,709,744)

(326,052,508)

Accumulated other comprehensive (loss) income

(5,231)

1,875

262

Total Pomdoctor Limited’s shareholders’ deficit

(2,263,421,920)

(2,335,705,081)

(326,051,856)

Noncontrolling interests

18,166

17,206

2,402

Total deficit

(2,263,403,754)

(2,335,687,875)

(326,049,454)

Total liabilities, mezzanine equity and deficit

46,227,586

43,871,949

6,124,287

 

 

 

POMDOCTOR LIMITED

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND

COMPREHENSIVE LOSS

For Six Months Ended June 30,

2024

2025

2025

RMB

RMB

US$

Net revenues – third parties

149,266,587

174,283,295

24,329,010

Net revenues – a related party

897,822

186,556

26,042

Net revenues

150,164,409

174,469,851

24,355,052

Cost of revenues

125,823,734

146,152,450

20,402,095

Gross profit

24,340,675

28,317,401

3,952,957

Operating expenses:

Sales and marketing expenses

24,884,898

27,761,736

3,875,389

General and administrative expenses

6,835,897

10,494,487

1,464,974

Research and development expenses

1,507,847

1,479,909

206,587

Impairment loss on long-lived assets

17,861

2,041,299

284,954

Total operating expenses

33,246,503

41,777,431

5,831,904

Loss from operations

(8,905,828)

(13,460,030)

(1,878,947)

Other income (expenses):

Other income

1,078,270

28,027

3,912

Other expense

(33,681)

(130,291)

(18,188)

Interest expense

(6,179,172)

(6,471,198)

(903,344)

Government grants

13,858

148,000

20,660

Total other expense, net

(5,120,725)

(6,425,462)

(896,960)

Loss before income tax

(14,026,553)

(19,885,492)

(2,775,907)

Income tax expense

Net loss

(14,026,553)

(19,885,492)

(2,775,907)

Accretion to redemption value of mezzanine equity

(52,695,272)

(52,405,735)

(7,315,559)

Less: Net income (loss) attributable to noncontrolling interests

27,639

(960)

(134)

Net loss attributable to the Pomdoctor Limited’s ordinary
   shareholders

(66,749,464)

(72,290,267)

(10,091,332)

Net loss

(14,026,553)

(19,885,492)

(2,775,907)

Other comprehensive (loss) income:

Total other comprehensive (loss) income

(3,970)

7,106

992

Total comprehensive loss

(14,030,523)

(19,878,386)

(2,774,915)

Accretion to redemption value of mezzanine equity

(52,695,272)

(52,405,735)

(7,315,559)

Less: comprehensive income (loss) attributable to noncontrolling
   interests

27,639

(960)

(134)

Comprehensive loss attributable to the Pomdoctor Limited’s
   ordinary shareholders

(66,753,434)

(72,283,161)

(10,090,340)

Loss per share

      Basic and diluted

(10.58)

(11.45)

(1.60)

Weighted average number of ordinary shares outstanding*

      Basic and diluted

6,310,198

6,310,198

6,310,198

*  Ordinary shares and share data have been retroactively restated to give effect to the nominal share issuance for
    the Reorganization completed on August 8, 2024

 

 

 

POMDOCTOR LIMITED

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

For Six Months Ended June 30,

2024

2025

2025

RMB

RMB

US$

Net cash used in operating activities 

(10,631,121)

(14,987,658)

(2,092,195)

Cash flows from investing activities:

Payment for purchase of property and equipment

(17,862)

(2,200)

(307)

Payment for long-term investment

(510,000)

(71,193)

Net cash used in investing activities

(17,862)

(512,200)

(71,500)

Cash flows from financing activities:

Loans from related parties

11,219,986

24,750,310

3,455,010

Repayment to related parties

(14,436,941)

(5,677,514)

(792,550)

Proceeds from short-term bank loans

37,000,000

29,000,000

4,048,244

Repayment of short-term bank loans

(19,300,000)

(29,250,000)

(4,083,143)

Repayment of long-term bank loans

(54,628)

(600,000)

(83,757)

Loans from third parties

8,759,366

1,600,000

223,351

Repayment to third parties

(4,968,912)

(5,982,272)

(835,093)

Payment for deferred offering cost

(1,656,745)

(252,478)

(35,245)

Net cash provided by financing activities

16,562,126

13,588,046

1,896,817

Effect of exchange rate changes

(3,970)

7,106

992

Net increase (decrease) in cash and cash equivalents and restricted
cash

5,909,173

(1,904,706)

(265,886)

Cash and cash equivalents and restricted cash at beginning of the
   period

6,805,099

7,651,695

1,068,135

POMDOCTOR LIMITED

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS — (Continued)

For Six Months Ended June 30,

2024

2025

2025

RMB

RMB

US$

   Including:

      Cash and cash equivalents at beginning of the period

6,717,031

7,651,695

1,068,135

      Restricted cash at beginning of the period

88,068

Cash and cash equivalents and restricted cash at end of the period

12,714,272

5,746,989

802,249

Including:

      Cash and cash equivalents at end of the period

12,714,272

5,746,989

802,249

Supplemental disclosures of cash flows information:

Cash paid for interest expense

1,130,609

2,382,125

332,532

Supplemental disclosure of noncash investing and financing activities:

Operating lease right-of-use assets obtained in exchange for new operating
    lease liabilities

2,039,099

284,647

 

The City of São Paulo has received GUINNESS WORLD RECORDS™ recognition for having the world’s largest municipal food security program

SÃO PAULO, Dec. 4, 2025 /PRNewswire/ — On Wednesday (December 3), the City of São Paulo received GUINNESS WORLD RECORDS™ recognition for having the world’s largest municipal food security program, making it the first city in the world to be recognized in this category. The achievement, which establishes the São Paulo model as an international benchmark, acknowledges the state capital’s permanent public policy of dignified and continuous access to food for the population. The record was established after a Guinness audit confirmed the distribution of 933.8 metric tons of food in 24 hours. The City of São Paulo distributes more than 3 million meals on a daily basis.

The São Paulo State capital distributes more than 3 million meals on a daily basis and gains international recognition
The São Paulo State capital distributes more than 3 million meals on a daily basis and gains international recognition

São Paulo Mayor, Ricardo Nunes, received the Guinness certificate from the institution’s adjudicator, Camila Borenstain, who attended the ceremony in Paraisópolis, a low-income community in the southern part of the city. Food security is considered a fundamental human right by the World Health Organization.

The food security network managed by the City includes ready-made meals, fresh produce, and staple food baskets. For official verification of the record, a historic mobilization took place on the so-called “Food Security D Day”, November 25, which involved more than 5,600 polling sites across the city and 1,500 people on the streets.

Upon receiving the certificate from the Guinness World Records’ official representative, Mayor Ricardo Nunes emphasized that this moment illustrates how much São Paulo is a city of solidarity, hospitality, and care for its population. “This achievement means a lot. Only those who have experienced hunger know what I’m talking about; only those who have seen someone going hungry understand the importance of a robust food program”, he said.

“Today, December 3, it is an honor to evaluate this record achieved by the city of São Paulo: the largest municipal public food security program”, said Guinness adjudicator Camila Borenstain.

Main programs

The main programs considered in the achievement include the one that distributes school meals, which provide up to five meals a day to more than 1 million students in the municipal school system. In the early childhood segment, 325,000 children in early childhood education receive milk at home every month.

For directly fighting social vulnerability, the City of São Paulo distributes a total of 421,000 staple food baskets per month through the Cestas Básicas (Staple Food Baskets) and Cidade Solidária (Solidary City) programs.

The network also includes Bom Prato Paulistano (Good São Paulo Food), with 7,000 affordable meals per day, in addition to Rede Cozinha Escola (School Kitchen Network), which delivers 26,000 meals per day and offers professional training, and Rede Cozinha Cidadã (Citizen Kitchen Network), which delivers 15,000 meals per day in the city’s outskirts.

These actions are complemented by Armazéns Solidários (Solidary Warehouses), which offer discounts of up to 50% on essential food items for those registered with the CadÚnico program, and Banco de Alimentos (Food Bank), which donates 55 metric tons of products per month to social institutions.